Webinar on patient preferences in multiple myeloma now online!


Multiple myeloma is a cancer that forms in plasma cells, a type of white blood cells. In our 1 April 2022 webinar, we presented the results of a multiple myeloma patient preference study that aimed to understand the unmet needs, treatment outcomes and attributes (side-effects, symptoms, efficacy outcomes) that are most important to multiple myeloma patients.

Isabelle Huys (KU Leuven), Rosanne Janssens (KU Leuven), Irina Cleemput (KCE) and Jayne Galinsky (Myeloma Patients Europe) explain in detail what methodologies (patient discussions, online survey methods) that we used, how patients and patients’ organisations contributed to the design and conduct of our study, and how the results can inform decision-making across the medicinal product life cycle, such as: industry in selecting clinical trial endpoints, regulators when assessing benefits and risks and HTA bodies for informing reimbursement of multiple myeloma treatments. 

Future PREFER events

Want to get specific? 

Last modified: 2021-11-10